The $287,000 GLP-1 Premium Bomb: What Mid Size Employers Need to Know

The Two Crises Colliding

American employers are facing a pharmaceutical cost shock unlike anything in recent memory. GLP-1 receptor agonists -- branded as Ozempic, Wegovy, Mounjaro, and Zepbound -- have become the fastest-growing drug class in employer-sponsored health plans, with individual patient costs ranging from $800 to $1,500+ per month. The Employee Benefit Research Institute (EBRI) projects that widespread GLP-1 utilization could increase employer health insurance premiums by 5.3% to 13.8%, depending on adoption rates.

The Kaiser Family Foundation's 2025 Employer Health Benefits Survey reports that 36% of large employers cite prescription drug prices as contributing "a great deal" to premium increases, while the Business Group on Health found that 79% of large employers are seeing increased GLP-1 utilization in their plans. Average family premiums have hit $26,993 -- a 6% increase for the third consecutive year, the first time this has occurred in two decades.

But here is where the crisis becomes asymmetric: large employers with self-funded plans can implement pharmacy carve-outs, formulary management, step therapy protocols, and direct GLP-1 manufacturer contracts to manage costs. Mid-size employers (30-200 employees) that remain fully insured have none of these tools. They absorb the full premium impact passed through by their carrier.

The second crisis magnifying this exposure is workforce composition. Blue-collar industries -- construction, manufacturing, transportation, and energy -- have workforces with higher obesity prevalence than the national average. CDC/NHANES data reports the national adult obesity rate at 41.9%. Workers in transportation and warehousing show obesity rates of 38.6%, and construction and manufacturing workers track at or above national averages. Higher obesity prevalence means higher GLP-1 demand, which means higher premium impact -- concentrated in the very industries least equipped to manage it.

The Framework: The GLP-1 Vulnerability Index

To quantify which employers face the greatest GLP-1 cost exposure, we developed the GLP-1 Vulnerability Index -- a composite score based on four factors: workforce obesity prevalence, percentage of employees in fully insured plans, average premium cost, and projected GLP-1 utilization rate.

Sources: CDC/NHANES (obesity); KFF 2025 EHBS (premiums, funding type); BIH analysis (vulnerability scoring). Fully insured percentage for mid-size firms estimated from KFF data showing 73% of workers at firms with 10-199 employees are NOT in self-funded plans.

Model Employer Profile: The $287,000 GLP-1 Bomb

Model Employer: 100-employee mid-size construction firm

• Average annual wage: $58,360 (BLS May 2024 median, construction)
• 70 employees enrolled in health plan (45 family, 25 single)
• Total annual health premium: $1,447,810 (45 x $26,993 + 25 x $9,325)
• Employer share (74%): $1,071,379
• Estimated workforce obesity rate: ~42%

The Hidden Math: GLP-1 Premium Impact

The 8% mid-range GLP-1 impact is derived from EBRI's projected range of 5.3%-13.8%. The self-funded 2.5% impact reflects pharmacy carve-out, step therapy, and formulary management capabilities available to self-funded employers.

When you add the base premium trend differential (fully insured at 7.5% vs. alternative at 3.5%) to the GLP-1 surcharge, the fully insured mid-size employer accumulates approximately $287,000 more in total health costs over 3 years than an identical employer that moved to self-funded with pharmacy carve-out.

The Correlation: Why Mid-Size Firms Get Hit 3x Harder

The 3x multiplier is not arbitrary. It reflects three compounding disadvantages:

First, fully insured carriers spread GLP-1 costs across their entire book of business, but mid-size group rates are more volatile than large group rates. Peterson-KFF reports that small group insurers are proposing median 11% premium increases for 2026, compared to 6% for large groups. GLP-1 costs amplify this disparity.

Second, fully insured mid-size employers cannot implement pharmacy carve-outs. In self-funded arrangements, employers can contract directly with PBMs, negotiate GLP-1 pricing, require step therapy (lifestyle modifications before drug coverage), and set formulary restrictions. Fully insured employers accept whatever the carrier decides.

Third, blue-collar workforces have higher baseline obesity rates, creating proportionally higher GLP-1 demand. A construction firm with 42% workforce obesity will see more GLP-1 utilization than a tech company with 28% -- and the fully insured construction firm has no tools to manage the cost.

Four Paws MA -- Premium Increase History

Prior PEO carrier name withheld. PEO4YOU 2026 medical increase of 2% compares to the 13% statewide average approved by MA DFS for 2026 small group plans.

"Sam helped our nonprofit organization secure stronger coverage with a better carrier and expanded network while also somehow reducing costs -- which was a huge win for our organization and all of our employees."

-- Kevin MacDonald, HR Manager, Four Paws MA

What a Strategic Benefits Redesign Would Cost

Transitioning from fully insured to an alternative funding structure that includes pharmacy management typically costs $20,000-$45,000 for a 100-employee firm (consulting, actuarial analysis, stop-loss placement, employee communication). This investment is recovered in the first 3-6 months of operation.

Conservative estimates based on 8% GLP-1 premium impact for fully insured vs. 2-3% managed impact for alternative funding, plus base trend differential. Actual savings depend on claims experience, group demographics, and plan design.

What This Means for Your Industry

Construction

Construction firms face the highest GLP-1 vulnerability due to the combination of above-average obesity rates and very low self-funded adoption. A 100-person general contractor could save $387,000-$474,000 over 3 years by moving to self-funded or captive structures with pharmacy carve-outs.

Manufacturing

Manufacturing has modestly higher self-funded adoption (32% vs. 27% overall for mid-size firms), but the majority remain fully insured and exposed. The lower median wage ($45,960) means the GLP-1 premium increase hits harder relative to total compensation.

Transportation & Warehousing

Transportation employers face the worst of both worlds: the lowest wages (making benefits the largest share of compensation), CDC-documented high obesity prevalence (38.6%), and the lowest self-funded penetration. PEO and Taft-Hartley structures are particularly suited to this sector, providing pooled pharmacy purchasing power.

Oil & Energy

Oil and energy employers benefit from higher wages but still face significant GLP-1 exposure, particularly for field operations workers. Captive consortiums tailored to the energy sector have shown strong results in managing specialty drug costs.

Why Brokers Aren't Showing This

If the GLP-1 premium bomb is this predictable, why aren't benefits brokers sounding the alarm?

The answer has three parts. First, most brokers earn commissions tied to premium volume -- higher premiums mean higher commissions. A $1.4M fully insured renewal generates $70,000-$112,000 in annual broker revenue at standard 5-8% commission rates. Moving to self-funded or PEO arrangements reduces premiums and, consequently, broker income.

Second, pharmacy carve-out design is a specialized skill. Building a self-funded program with PBM negotiation, formulary management, step therapy protocols, and stop-loss pharmacy aggregating factors requires actuarial and clinical expertise most retail brokers do not possess.

Third, many brokers simply don't model GLP-1 impact separately. They see a 10% renewal and negotiate it down to 8% without disaggregating the pharmacy component. A strategic benefits consultant would identify the GLP-1 driver, model alternative scenarios, and present the employer with funding options that specifically address pharmacy cost management.

References

1. BIH Model Estimate, March 2026. Based on 100-employee construction firm, 70 enrolled (45 family/25 single), $1,447,810 annual premium, 8% GLP-1 impact fully insured vs. 2.5% with pharmacy carve-out, compounded at 7.5% vs. 3.5% annual trend over 3 years.
2. GLP-1 drug costs: Ozempic/Wegovy (Novo Nordisk) and Mounjaro/Zepbound (Eli Lilly) list prices range $800-$1,500+/month. Source: manufacturer pricing, GoodRx, CMS data.
3. Employee Benefit Research Institute (EBRI). Impact of GLP-1 Drugs on Employer Health Insurance Premiums. ebri.org. Projects 5.3%-13.8% premium increase depending on utilization.
4. KFF Employer Health Benefits 2025 Survey (36% cite Rx prices) and Business Group on Health 2026 Employer Health Care Strategy Survey (79% increased GLP-1 utilization).
5. KFF. Employer Health Benefits 2025 Annual Survey. kff.org. Family premiums $26,993, 6% increase for 3rd consecutive year.
6. CDC/NHANES. National Health and Nutrition Examination Survey. Adult obesity prevalence 41.9%. cdc.gov.
7. CDC. Obesity Prevalence by Occupation. Transportation/warehousing workers 38.6%. Construction and manufacturing at or above national average.
8. KFF. Employer Health Benefits 2025 Survey. 27% of workers at firms 10-199 in self-funded plans; 73% in fully insured or level-funded.
9. EBRI GLP-1 premium impact range 5.3%-13.8%. Mid-range 8% used for fully insured. Self-funded 2.5% reflects pharmacy carve-out, step therapy, formulary management.
10. BIH Analysis. $287,000 total 3-year gap includes base trend differential (7.5% vs. 3.5%) plus GLP-1 surcharge differential (8% vs. 2.5%).
11. Peterson-KFF Health System Tracker. Small group median proposed increase 11% for 2026 vs. 6% for large groups.
12. Self-funded pharmacy carve-out capabilities: PBM contracting, formulary management, step therapy. Source: Mercer, Aon benefits consulting research.
13. CDC/NHANES obesity data by occupation. Higher baseline obesity = higher GLP-1 utilization = higher premium impact.
14. Implementation costs for 100-employee transition to self-funded: $20,000-$45,000 industry standard. Source: Mercer, Aon implementation guides.
15. Construction savings: self-funded/captive 3-year cumulative based on BIH modeling with 8% base reduction and 3.2-3.5% trend.
16. Manufacturing self-funded adoption: 32% vs. 27% for all firms under 200. Source: KFF 2025 EHBS.
17. Transportation obesity 38.6% (CDC); lowest self-funded penetration among target sectors. PEO/Taft-Hartley suited for pooled pharmacy purchasing.
18. Oil/energy captive performance in managing specialty drug costs. Source: WTW energy sector captive data.
19. Broker commission: 5-8% of fully insured premiums. Source: Mercer, Aon compensation surveys.

About the Author: Sam Newland, CFP®, has spent 13+ years in the employee benefits industry and founded Business Insurance Health and PEO4YOU to bring transparency to an industry that profits from complexity. His approach is simple: show employers the real numbers and let them decide.